Bevacizumab purification by peptide affinity chromatography

G. R. BARREDO; GIUDICESSI, S.L.; M. C. MARTÍNEZ CERON; S. L. SAAVEDRA; G, MAHLER; F. ALBERICIO; O. CASCONE; CAMPERI, S.A.

Proceedings of the 35th European Peptide Symposium

EPS

Año: 2019; p. 130 - 132

Therapeutic Monoclonal Antibodies (mAbs) are widely used in the treatment of many diseases. Bevacizumab(trade name: Avastin) inhibitsthe vascular endothelial growth factor and hence the angiogenesis process. It isused in brain, breast, colorectal, lung and renal cancer treatments (1). Due to its parenteral administration,its degree of purity must be extremely high. Nowadays, that is achieved by affinity chromatography (AC)with immobilized proteinA, a highly expensive ligand that increases the cost of the purification process. On theother hand, short peptides are ideal ligands for AC due to their higher stability, easier synthesis and lowercost in comparison to protein A (2). In this work, a short peptide ligand with affinity for Bevacizumab wasselected from a peptide library